Voyager Therapeutics (NASDAQ:VYGR) Rating Reiterated by HC Wainwright

Voyager Therapeutics (NASDAQ:VYGR)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a research report issued on Thursday, Benzinga reports. They currently have a $30.00 target price on the stock. HC Wainwright’s price target indicates a potential upside of 358.02% from the company’s previous close.

A number of other analysts also recently commented on the stock. StockNews.com upgraded shares of Voyager Therapeutics from a “hold” rating to a “buy” rating in a report on Friday, October 11th. Leerink Partnrs raised Voyager Therapeutics to a “strong-buy” rating in a report on Wednesday, October 16th. Leerink Partners assumed coverage on Voyager Therapeutics in a research note on Wednesday, October 16th. They set an “outperform” rating and a $15.00 price objective on the stock. Finally, Wedbush cut their target price on Voyager Therapeutics from $8.00 to $7.00 and set a “neutral” rating for the company in a research note on Wednesday, August 7th. One analyst has rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $17.43.

Voyager Therapeutics Stock Performance

Shares of VYGR traded up $0.12 during trading hours on Thursday, hitting $6.55. 325,842 shares of the stock were exchanged, compared to its average volume of 644,989. The stock’s 50-day moving average price is $6.55 and its two-hundred day moving average price is $7.65. Voyager Therapeutics has a 12-month low of $5.71 and a 12-month high of $11.72. The company has a market cap of $357.17 million, a price-to-earnings ratio of 23.32 and a beta of 0.91.

Voyager Therapeutics (NASDAQ:VYGR) last released its earnings results on Tuesday, August 6th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.38) by $0.20. The business had revenue of $29.58 million during the quarter, compared to analyst estimates of $11.52 million. Voyager Therapeutics had a net margin of 6.28% and a return on equity of 3.31%. During the same quarter in the prior year, the firm earned ($0.51) earnings per share. On average, research analysts expect that Voyager Therapeutics will post -1.27 earnings per share for the current year.

Insider Buying and Selling at Voyager Therapeutics

In other news, insider Sandell Jacquelyn Fahey sold 5,999 shares of the stock in a transaction on Wednesday, October 2nd. The stock was sold at an average price of $5.82, for a total transaction of $34,914.18. Following the completion of the transaction, the insider now directly owns 86,001 shares in the company, valued at approximately $500,525.82. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 4.53% of the company’s stock.

Hedge Funds Weigh In On Voyager Therapeutics

Several large investors have recently made changes to their positions in VYGR. Great Point Partners LLC acquired a new stake in Voyager Therapeutics in the 2nd quarter valued at approximately $12,668,000. Farallon Capital Management LLC raised its holdings in shares of Voyager Therapeutics by 77.4% in the 1st quarter. Farallon Capital Management LLC now owns 2,292,000 shares of the company’s stock valued at $21,339,000 after buying an additional 1,000,000 shares during the period. Vanguard Group Inc. raised its holdings in shares of Voyager Therapeutics by 27.8% in the 1st quarter. Vanguard Group Inc. now owns 3,231,698 shares of the company’s stock valued at $30,087,000 after buying an additional 702,030 shares during the period. Armistice Capital LLC lifted its stake in Voyager Therapeutics by 11.3% during the 2nd quarter. Armistice Capital LLC now owns 5,200,000 shares of the company’s stock worth $41,132,000 after acquiring an additional 528,000 shares in the last quarter. Finally, American Century Companies Inc. boosted its holdings in Voyager Therapeutics by 32.4% during the 2nd quarter. American Century Companies Inc. now owns 1,019,332 shares of the company’s stock valued at $8,063,000 after acquiring an additional 249,659 shares during the period. 48.03% of the stock is currently owned by institutional investors and hedge funds.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.